Kornimate/medical-research-clean huggingface dataset:
characteristics of plant sterols consumers in france

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to describe the cardiovascular risk profile in subjects who consume a marketed drinkable low fat fermented milk enriched with plant sterol. investigations are lead prospectively and retrospectively among adults enrolled from general practitioners' database.


Eligibility criteria:
inclusion criteria: * male and female aged 18-70 years, regular visits to gp (at least once every six months within the past 2 years), agreeing to a written informed consent exclusion criteria: * any clinical, psychological or language problem that would prevent from completing the questionaires or communicating with gp

Keywords: cardiovascular risk dairy enriched product with plant sterols general practitioners adults followed by general practitioners
individualized rtms for motor recovery in stroke patients

Conditions: Stroke; Transcranial Magnetic Stimulation

Summary: this study aimed to aim to investigate the efficacy of individualized rtms according to lateralization index on motor recovery and cortical excitability in subacute stroke patients.

repetitive transcranial magnetic stimulation (rtms) is a non-invasive neuromodulation technology. high and low frequencies of rtms could modulate the excitability of the cerebral cortex. theta burst stimulation (tbs) has achieved a similar effect to traditional rtms mode. however, the current rtms studies for stroke patients utilized the same therapeutic protocol and there is no individualized rtms protocol based on the value of lateralization index. this study aimed to aim to investigate the efficacy of individualized rtms according to lateralization index on motor recovery and cortical excitability in subacute stroke patients.

Eligibility criteria:
inclusion criteria: 1. unilateral ischemic or hemorrhagic stroke 2. stroke within 3 months 3. medical research council scale for muscle strength in upper limb ≤ 3 4. no previous stroke, seizure, dementia, parkinson's disease or other degenerative neurological diseases. 5. patient could sit over 15 minutes 6. age over 20 exclusion criteria: 1. previous stroke, traumatic brain injury, brain tumor 2. with central nervous system disease (spinal cord injury, parkinson's disease) 3. any contraindication to rtms (seizure, alcoholism, metal implant, pacemaker) 4. patients unable to cooperate the treatment 5. pregnancy 6. depression
study to evaluate the efficacy of a micro coring device for the treatment of scars of the cytrellis micro-coring device for the treatment of scars

Conditions: Scars

Summary: a study to evaluate the safety and effectiveness of a micro coring device for the treatment of scars.

the study subject population will consist to up to 30 subjects who meet the inclusion/exclusion criteria. all subjects will be monitored for a period of 6 months post last treatment. an study results will be assessed on the following: * posas - patient observer scar assessment * asas - acne scar severity scale * subject satisfaction scale

Eligibility criteria:
inclusion criteria: * 18 years of age or older * fitzpatrick scale i-vi. * any type of scar except for keloid scars * able to provide written informed consent, understand and willing to comply with study related procedures and follow-ups. exclusion criteria: * previous treatment of the scar tissue within last 6 months. * silicone, fat, collagen or synthetic material in the treatment area. * history of keloid formation. * active smokers (smoking more than ½ pack per day) or having quit smoking (½ pack per day) for less than 3 months. * active, chronic, or recurrent infection. * compromised immune system (e.g. diabetes). * hypersensitivity to analgesic agents. * co-morbid condition that could limit ability to participate in the study or to comply with follow-up requirements. * pregnant or breastfeeding. * any issue that, at the discretion of the investigator, would contra-indicate the subject's participation. * any medication that may cause bleeding such as anticoagulants. * allergy to lidocaine and/or epinephrine

Keywords: acne scars stretchmarks surgical scars
femorofemoral bypass in redo cardiac surgery

Conditions: Heart Valve Diseases

Summary: redo cardiac surgery are becoming more common with a patient population at greater risk. sternal re-entry poses the hazard of probable injury to vital structures. to minimize the risk associated with sternal re-entry, the investigators adopted the method of establishing femoral artery-femoral vein cardiopulmonary bypass (cpb).

redo cardiac surgery are more frequent with a patient population at greater risk. repeat sternal entry poses the risk of possible injury to vital structures. these include laceration of the myocardium, especially the right ventricle, injury of great vessels or crossing coronary bypass grafts as the internal mammary grafts in particular, or dislodgement of emboli from patent vein grafts. to minimize the risk associated with sternal re-entry, the investigators adopted the method of establishing femoral artery-femoral vein cardiopulmonary bypass (cpb) in order to achieve cardiac drain prior to sternotomy. also, femorofemoral bypass support the hemodynamics in cases of redo emergency cardiac surgery.

Eligibility criteria:
inclusion criteria: * 25-65 years old * patients scheduled for repeat open heart surgery with sternotomy * informed consent has been obtained exclusion criteria: * planned off-pump cardiac surgery * vascular disease * previous operation on femoral artery * under 25 years of age

Keywords: femoro-femoral bypass
vaccination efficacy with metformin in older adults

Conditions: Aging; Age-Related Immunodeficiency; Vaccine Response Impaired

Summary: with aging the immune system gets weaker. this makes older adults more susceptible to influenza (flu). vaccinations help to prevent infection from the flu virus, however the immune system of older adults do not respond as well to vaccines compared to young adults and thus, aren't as well protected from the complications from the flu. this research is being done to determine if metformin, an fda-approved diabetes medication, is effective at enhancing immune responses to flu vaccine in older men and women. participants will be randomly assigned to either metformin or placebo treatment for a total of 22 weeks. participants will be vaccinated with high-dose flu vaccine after 12 weeks of treatment. immune responses will be evaluated throughout the study at 6 time points.


Eligibility criteria:
inclusion criteria: * men and women 65 years and older * willingness to provide consent and participate in all aspects of the trial including randomization to the intervention group and receiving this year's flu vaccine * received previous year's seasonal influenza vaccine exclusion criteria: * history of severe renal impairment and/or egfr ≤ 45 ml/min/1.73m2 * excessive alcohol use (more than 14 alcoholic drinks/week) or clinical/laboratory evidence of hepatic disease (via medical history and/or ast and/or alt ≥ 3 times upper limit of normal at screening) * acute or chronic metabolic acidosis (via medical history and/or low serum bicarbonate (\ 10 meq/l)) * history of b12 deficiency within the last 10 years * known type 2 diabetes or screening of prediabetic (hba1c 5.7-6.4%) or diabetic (hba1c ≥ 6.5%) * currently taking metformin or other diabetes medications * unwilling or unable (due to significant cognitive impairment) to provide informed consent * terminal illness with life expectancy less than 12 months * advanced neurological disorder (parkinson's, als, ms, dementia) * cancer or history of cancer in the past 2 years (excluding non-melanoma skin cancer) or any history of metastatic (stage 4) cancer * significant co-morbid disease (severe chronic obstructive pulmonary disease, active rheumatologic diseases, chronic infection (hiv, tuberculosis), severe congestive heart failure (nyha class 4), myocarditis, etc) * myocardial infarction, stroke or hospitalization for heart failure in the last 12 months * severe active psychiatric disorder (e.g. bipolar, schizophrenia) * unable to complete physical performance testing due to medical conditions (at discretion of the pi) * uncontrolled hypertension (systolic/diastolic blood pressure \>150/90 mmhg) * unintentional weight loss \>10% in past 12 months * allergy or history of adverse reaction to flu vaccine or any ingredients in flu vaccine, including eggs * history of guillain-barre syndrome following vaccination * immunosuppressive disorders or taking immunosuppressive medications (including oral prednisone \> 10mg/day) * current participation in another interventional study * refusal to receive flu vaccine
intestinal microbiota of patients hospitalized with sars-cov-2

Conditions: COVID-19

Summary: the study investigators hypothesize that sars-cov2 infection alters the composition of the digestive microbiota and its functionality, resulting in changes in intestinal permeability and consequently in microbial digestive translocation. these changes may correlate with the magnitude of the sars-cov-2 viral load in the gastrointestinal tract and may have an impact on the clinical manifestations and evolvability of covid-19.


Eligibility criteria:
inclusion criteria: * patient hospitalized at in nimes university hospital * infection with sars-cov-2 confirmed by rt-pcr * the patient must have signed the consent form * the patient must be a member or beneficiary of a health insurance plan exclusion criteria: * the subject is participating in an interventional study susceptible to modify the intestinal microbiota, or is in a period of exclusion determined by a previous study * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * patient with a chronic digestive pathology or having been operated in the previous year or having enteral nutrition or having had bariatric surgery * patient is pregnant, parturient or breastfeeding

Keywords: microbiota gastrointestinal microbiome translocation
chromatic and monochromatic optical aberrations after corneal refractive surgery

Conditions: Refractive Errors; Aberration, Corneal Wavefront

Summary: refractive surgeries can be divided into two distinct categories: 1) corneal surgeries (superficial and deep procedures) carried on the surface of the eye and 2) lens surgeries (phakic iol, refractive lens exchange) - an intraocular intervention, performed in the anterior or posterior chamber or on the lens. in the proposed protocol focus is on the corneal refractive surgeries impact on monochromatic higher-order aberrations on the one hand and chromatic aberrations on the other. during the surgery in order to get the patient emmetropic, refractive surgery corrects optical defects by decreasing aberrations of lower orders ) simultaneously increases high-order aberrations (that is perceived by the patient as halo, glare or starburst). informations about prevalence and causes of higher order aberrations after refractive surgery are numerous but there is no information about chromatic aberrations.


Eligibility criteria:
inclusion criteria: * patient after corneal refractive surgery at least for 4 months * post surgical refraction within +/- 0.75 diopter of spherical and +/- 1.0 diopter of cylindrical error * willing and able to understand and sign an informed consent form. exclusion criteria: * patient unable to participate in the study * any corneal diseases, eyes trauma or systemic diseases history; keratoconus or tendency of keratoconus * corneal macula and obvious pannus; current enrolment in another clinical trial/research project
contrast enhanced ultrasound in covid-19

Conditions: Covid19; Multisystem Inflammatory Syndrome in Children (MIS-C)

Summary: initial data from covid-19 patients suggests that one of the primary causes of death is significant endothelial injury leading to blood clotting and impaired multiorgan microvascular perfusion. the current study uses a safe, convenient bedside imaging tool called contrast-enhanced ultrasound (ceus) to estimate the extent of microvascular perfusion impairment in the heart, kidneys and/or brain of covid-19 pediatric patients in vivo and assess the significance of imaging findings by correlating to clinical outcomes. this pilot study will be conducted at one site, the children's hospital of philadelphia. the investigators plan to enroll and evaluate 30 patients.

the current study uses a safe, convenient bedside imaging tool called contrast-enhanced ultrasound (ceus) to measure the extent of microvascular perfusion impairment in the heart, kidneys and/or brain of covid-19 pediatric patients and, as exploratory analysis, to assess the significance of imaging findings by correlating to clinical outcomes. sulfur hexafluoride lipid-type a microspheres (lumasontm, bracco inc) is an fda-approved ultrasound contrast agent. contrast-enhanced ultrasound scan with a duration of approximately 15 minutes will be performed when a covid-19 diagnosis has been made (or is highly suspected) according to established clinical procedures. one ceus will be performed per patient, with up to 2 intravenous injections of the contrast agent. the dosing plan will be weight-adjusted, based on a dose of 0.03 ml/kg (with a maximum dose of 2.4 ml per injection). organ perfusion will be evaluated in the heart, kidneys, and/or brain. clinical outcomes during hospital stay will be collected for correlation to ceus-based measures.

Eligibility criteria:
inclusion criteria: 1. patient (male/female) hospitalized at the children's hospital of philadelphia (chop). 2. patient 17 years of age or younger. 3. diagnosis of covid-19 or high clinical suspicion for covid-19 despite negative tests (according to the definition of probable case by the european centre for disease prevention and control). 4. patients have evidence of cardiovascular compromise, myocardial injury, acute kidney injury and/or new-onset neurological symptoms. 5. parental/guardian permission (informed consent) exclusion criteria: 1. medical history of lumason hypersensitivity

Keywords: ultrasound contrast-enhanced ultrasound
gabapentin for the treatment of hot flashes in menopausal women

Conditions: Hot Flashes; Menopause

Summary: the purpose of this study is to evaluate the effectiveness and safety of gabapentin compared to placebo in the treatment of hot flashes in postmenopausal women using a phase iii randomized controlled trial.

for women who fear developing breast cancer, those who have contraindications to hormone replacement therapy and those who prefer an alternative treatment, there is presently no standard treatment for hot flashes. women and health care providers have few options other than hormone replacement therapy as evidenced-based trials of alternatives have not shown many effective options. many non-hormonal agents have been studied including antidepressants, antihypertensives, vitamin e, soy products, black cohosh, acupuncture, and belladonna and ergotamine combinations. preliminary studies using the antiseizure medication, gabapentin (neurontin), has demonstrated a substantial reduction in hot flashes. this agent may provide an effective treatment for hot flashes in postmenopausal women.

Eligibility criteria:
inclusion criteria: * women with substantial hot flashes defined as reporting at least 14 hot flashes per week. * postmenopausal women as defined by the natural cessation of menses for 1 year. * aged 45 - 65 years. exclusion criteria: * women on hormone replacement therapy. * women with a surgically induced menopause (oophorectomy). * women on tamoxifen or receiving chemotherapy/radiation therapy or planned antineoplastic chemotherapy/radiation therapy. * renal function impairment (serum creatinine greater than the laboratory normal range; or creatinine clearance \<30ml/min). * use of antidepressants with serotonin reuptake mechanisms and antiseizure medications within the past month. * neurologic conditions: seizures, vertigo, and syncope. * known hypersensitivity to gabapentin and its components. * inability to complete questionnaires for any reason including psychiatric disorders. * history of a hypothalamic dysfunction. * life expectancy less than 6 months.

Keywords: gabapentin hot flashes or flushes menopause
clinical and biological strokes collection in reunion island

Conditions: Stroke

Summary: cross-sectional regional multicenter hospital study of all neurological events (stroke, ait and mimics) for diagnostic and prognostic purposes. cost of illness study.


Eligibility criteria:
inclusion criteria: * affiliated to a social security scheme * clinical signs suggestive of stroke : hemiparesis or hemiplegia, unilateral sensory disorder, language disorder, balance disorder, dizziness, loss of total or partial bilateral or monocular vision, sudden neurological deficit exclusion criteria: * current pregnancy * recent clinical history of head trauma * patients aged \< 18 years old * patient under guardianship or curatorship * person deprived of liberty
perfect project - part 1 - study 3

Conditions: Diabetes Prevention; Obesity Prevention

Summary: the objectives are to test the acute effects of different bagels containing pulse ingredients on: 1) post-prandial blood glucose, insulin and appetite for two hours, and 2) food intake two hours following consumption of pulse products. the investigators hypothesize that bagels containing pulse ingredients will lead to lower blood glucose, insulin, appetite and food intake responses compared to non-pulse bagels.


Eligibility criteria:
inclusion criteria: * normoglycemic (\<5.6 mmol/l) and normotensive (systolic blood pressure \<140 mm hg and diastolic blood pressure below \< 90 mm hg) * bmi of 18.5-29.9 kg/m2 exclusion criteria: * restrained eaters * regularly skip breakfast * smokers * those who are active (organized activities or athletic training at a high intensity; ≥ 150 min per week of moderate to vigorous physical activity) * those on medications that may influence study outcomes or have experienced any gastrointestinal related health conditions/surgeries over the past year. * those unable to walk for an hour continuously
treosulfan based conditioning myelodysplastic syndrome (mds)

Conditions: Myelodysplastic Syndrome

Summary: this is a multicenter, multinational, non-randomized, non-controlled open-label phase ii trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell transplantation (sct) in patients with mds. the aim is to demonstrate a clinical benefit compared to historical data with intravenous busulfan.


Eligibility criteria:
inclusion criteria: 1. patients with myelodysplastic syndrome, (mds) according to who classification (\< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation 2. availability of an hla-identical sibling donor (mrd) or hla-identical unrelated donor (mud) hla-identity defined by the following markers: hla-a, -b, -drb1, dqb1. 3. target graft size (unmanipulated) bone marrow: 2 to 10 x 106 cd34+ cells/kg bw recipient or at least 2 x 108 nucleated cells /kg bw or peripheral blood: 4 to 10 x 106 cd34+ cells/kg bw recipient 4. age \> 18 and \< 60 years 5. karnofsky index \> 80 % 6. adequate contraception in female patients of child-bearing potential 7. written informed consent exclusion criteria: 1. 'secondary' or therapy-related mds with known history of exposure to cytotoxic alkylating drugs and/or radiation therapy 2. previous aml-induction therapy with more than two courses (e.g. in case of blast excess) 3. previous allogeneic transplantation 4. severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or cardiac function) 5. known and manifested malignant involvement of the cns 6. active infectious disease 7. hiv- positivity or active hepatitis infection 8. impaired liver function (bilirubin \> upper normal limit; transaminases \> 3.0 x upper normal limit) 9. impaired renal function (creatinine-clearance \ 1.5 x upper normal limit). 10. pleural effusion or ascites \> 1.0 l 11. pregnancy or lactation 12. known hypersensitivity to treosulfan and/or fludarabine 13. participation in another experimental drug trial within 4 weeks before study 14. non-co-operative behaviour or non-compliance 15. psychiatric diseases or conditions that might impair the ability to give informed consent

Keywords: treosulfan mds allogeneic stem cell transplantation leukemia conditioning
prospective quality of life study in pituitary surgery

Conditions: Post Operative Care; Endoscopic Skull Base Surgery; Postoperative Period

Summary: post-operative assessment and debridement are key components in patient care for surgery patients. however, a standardized protocol for management after endoscopic skull base surgery is unavailable. in this study, investigators will observe the effect of various follow-up schedules on the patient's quality of life after surgery. patients who received surgery for pituitary adenoma will be placed randomly in 1 of 3 groups (short-term = follow-up in 2 weeks and 8 weeks after surgery; intermediate = 4 weeks and 8 weeks; long-term = 8 weeks). at each visit, patients will be asked to complete a packet of surveys and questionnaires that provide metrics on their quality of life in addition to receiving standard patient care (post-operative assessment and nasal debridement). researchers hope to find that a follow-up schedule that has patients visiting the clinic closer to their surgery date will increase the patient's quality of life after surgery.


Eligibility criteria:
inclusion criteria: * has surgery for pituitary adenoma at uva after may 1st, 2018 * has sellar and parasellar pathology * ≥ 18 years old * can complete all parts of study in english exclusion criteria: * extended approaches * use of naso-septal flap during the current surgical procedure * septoplasty * prior history of chronic rhinosinusitis (crs) * prior history of sphenoidotomy * \< 18 years old * prisoner